Dare Bioscience (DARE)
(Real Time Quote from BATS)
$0.30 USD
+0.01 (3.73%)
Updated Apr 26, 2024 02:42 PM ET
2-Buy of 5 2
F Value D Growth D Momentum F VGM
Cash flow Statements
Fiscal Year End for Dare Bioscience, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -30.16 | -30.95 | -38.70 | -27.40 | -14.26 |
Depreciation/Amortization & Depletion | 0.04 | 0.02 | 0.03 | 0.04 | 0.01 |
Net Change from Assets/Liabilities | -11.34 | 10.70 | 8.73 | 1.54 | 0.71 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 2.61 | 2.14 | 1.18 | 0.58 | 0.23 |
Net Cash From Operating Activities | -38.86 | -18.09 | -28.76 | -25.23 | -13.32 |
Property & Equipment | -0.63 | -0.06 | -0.01 | -0.02 | 0.00 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 6.14 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -0.63 | -0.06 | -0.01 | -0.02 | 6.14 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 15.37 | 1.34 | 75.85 | 24.76 | 5.15 |
Issuance (Repayment) of Debt | 0.27 | 0.00 | 0.00 | 0.37 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | 15.64 | 1.34 | 75.85 | 25.13 | 5.15 |
Effect of Exchange Rate Changes | -0.01 | -0.20 | -0.06 | 0.01 | -0.01 |
Net Change In Cash & Equivalents | -23.86 | -17.00 | 47.00 | -0.11 | -2.03 |
Cash at Beginning of Period | 34.67 | 51.67 | 4.67 | 4.78 | 6.81 |
Cash at End of Period | 10.81 | 34.67 | 51.67 | 4.67 | 4.78 |
Diluted Net EPS | -0.35 | -0.37 | -0.63 | -0.91 | -0.97 |
Fiscal Year End for Dare Bioscience, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | -30.16 | -25.10 | -16.80 | -8.04 |
Depreciation/Amortization & Depletion | NA | 0.04 | 0.03 | 0.02 | 0.01 |
Net Change from Assets/Liabilities | NA | -11.34 | -7.49 | -7.18 | -8.70 |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | NA | 2.61 | 1.89 | 1.26 | 0.62 |
Net Cash From Operating Activities | NA | -38.86 | -30.68 | -22.70 | -16.12 |
Property & Equipment | NA | -0.63 | -0.02 | 0.00 | 0.00 |
Acquisition/ Disposition of Subsidiaries | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | NA | -0.63 | -0.02 | 0.00 | 0.00 |
Uses of Funds
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | 15.37 | 9.86 | 1.75 | 1.30 |
Issuance (Repayment) of Debt | NA | 0.27 | 0.47 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | NA | 15.64 | 10.33 | 1.75 | 1.30 |
Effect of Exchange Rate Changes | NA | -0.01 | -0.07 | -0.05 | -0.02 |
Net Change In Cash & Equivalents | NA | -23.86 | -20.44 | -21.01 | -14.84 |
Cash at Beginning of Period | NA | 34.67 | 34.67 | 34.67 | 34.67 |
Cash at End of Period | NA | 10.81 | 14.23 | 13.66 | 19.83 |
Diluted Net EPS | NA | -0.07 | -0.09 | -0.10 | -0.09 |